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Karina Karolina Kedzior* and Lisa Tabata LaeberAbstract
Background: The aim of the current study was to investigate the association between anxiety and cannabis use/
cannabis use disorders in the general population.
Methods: A total of N = 267 studies were identified from a systematic literature search (any time- March 2013) of
Medline and PsycInfo databases, and a hand search. The results of 31 studies (with prospective cohort or
cross-sectional designs using non-institutionalised cases) were analysed using a random-effects meta-analysis
with the inverse variance weights. Lifetime or past 12-month cannabis use, anxiety symptoms, and cannabis use
disorders (CUD; dependence and/or abuse/harmful use) were classified according to DSM/ICD criteria or scores on
standardised scales.
Results: There was a small positive association between anxiety and either cannabis use (OR = 1.24, 95% CI:
1.06-1.45, p = .006; N = 15 studies) or CUD (OR = 1.68, 95% CI: 1.23-2.31, p = .001; N = 13 studies), and between
comorbid anxiety + depression and cannabis use (OR = 1.68, 95% CI: 1.17-2.40, p = .004; N = 5 studies). The positive
associations between anxiety and cannabis use (or CUD) were present in subgroups of studies with ORs adjusted
for possible confounders (substance use, psychiatric illness, demographics) and in studies with clinical diagnoses of
anxiety. Cannabis use at baseline was significantly associated with anxiety at follow-up in N = 5 studies adjusted for
confounders (OR = 1.28, 95% CI: 1.06-1.54, p = .01). The opposite relationship was investigated in only one study.
There was little evidence for publication bias.
Conclusion: Anxiety is positively associated with cannabis use or CUD in cohorts drawn from some 112,000
non-institutionalised members of the general population of 10 countries.
Keywords: Anxiety disorders, Cannabis use, Cannabis use disorders (dependence, abuse), Systematic review,
Meta-analysisBackground
The prevalence of affective and anxiety disorders is high,
particularly in the western world. According to the annual
Health Report 2012 of the second largest national health
insurer in Germany (Techniker Krankenkasse), the absence
from work due to a diagnosed psychiatric disorder had in-
creased by about 70% from 2000–2012 among clients in-
sured with the company [1]. Next to depression, the most
frequent of these diagnoses were different subtypes of
anxiety disorders. Although such an extreme increase in* Correspondence: kkedzior@graduate.uwa.edu.au
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distribution, and reproduction in any mediumprevalence of psychiatric illness was not confirmed
based on the national survey data in Germany and other
European Union (EU) countries over the same period of
time [2], it is clear that psychiatric illnesses are common
worldwide and substantially contribute to an overall disease
burden. According to nationally-representative samples of
adults, particularly the anxiety disorders occur frequently
with a lifetime prevalence of <10% in China, Israel, Nigeria,
and Japan, between 10-20% in the EU, Ukraine, Mexico,
South Africa, and Lebanon, and >20% in France, New
Zealand, Columbia, and the highest prevalence of 31% in
the USA [2,3]. Not surprisingly, compared to older adults
(65+ years of age), the high rates of anxiety disorders areentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited.
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years of age) during the challenging phase of life associ-
ated with establishment of professional career paths and
long-term relationships/family [3]. Similarly to adults, the
12-month estimates show that anxiety disorders are also
the most commonly occurring disorders in 13–17 year old
adolescents in the USA [4]. Furthermore, the Australian
data (from The National Survey of Mental Health and
Wellbeing) suggest that more females (32%) than males
(20%) experience anxiety disorders (especially the post-
traumatic stress disorder, PTSD) in their lifetime [5].
After alcohol and nicotine, cannabis is the most widely
consumed illicit substance [6,7] with an estimated 13.1
million dependent users worldwide in 2010 [8]. Interest-
ingly, the highest estimated cumulative incidence of can-
nabis use (42%) was observed in the two countries with
the highest rates of anxiety disorders- the USA and New
Zealand [6]. These findings suggest that anxiety and can-
nabis use might be related either directly or indirectly
via common factors. However, the empirical evidence so
far suggests that, among psychiatric disorders, cannabis
use is most consistently associated only with psychosis
[9]. According to meta-analyses, such an association is
particularly strong in frequent users compared to ever
users [10], early cannabis use increases the odds of later
psychosis [11], cannabis use (independent of gender or
heaviness of use) is related to an earlier onset of psych-
osis by about 3 years [12], and cannabis use disorders
are observed in particularly younger, male, first-episode
patients with schizophrenia [13]. In contrast, heavy or
problematic cannabis use was only moderately related to
depression outcomes [10,14,15] and anxiety [16]. How-
ever, such associations were often eliminated after con-
trolling for confounding factors, such as other substance
use and/or other psychiatric comorbidity [16-18]. This
result is not surprising because cannabis use is strongly
associated with the use of other substances, especially
nicotine [19], and nicotine use and dependence are re-
lated to some anxiety disorders, such as panic disorder
and generalised anxiety disorder [20]. Similarly, clinical
comorbidities frequently exist among different subtypes
of anxiety disorders and depression [21] or alcohol use
disorders [22]. Regardless of these possible confounders,
a systematic, quantitative assessment of comorbidity be-
tween anxiety and cannabis use is needed because both
conditions commonly occur in the general population,
particularly during the most productive yet stressful life-
phases (adolescent-middle age). If the two conditions co-
exist after controlling for confounders then this result
might have some implications for clinical treatment and
policy making. Specifically, the methods of detection and
treatment of both conditions concurrently might need
to be reassessed to provide effective patient care [23].
Such treatment could reduce any misdiagnoses becausethe acute effects of cannabis use resemble symptoms of
anxiety disorders, such as panic attacks [16]. However,
those seeking treatment for symptoms of anxiety may
not disclose their cannabis use due to the illegal nature
of this activity [14]. Furthermore, the link to anxiety
could also be used as supplementary evidence for devel-
opment of a rational cannabis policy that currently dif-
fers among countries worldwide [24].
To the best of our knowledge, only one systematic re-
view so far attempted to quantify the association between
cannabis use and anxiety disorders [10]. The authors listed
the effect sizes based on N = 7 studies using nationally-
representative cohorts and focusing on the association be-
tween ‘cannabis exposure’ and ‘anxiety outcomes’ (Figure
six of the article). However, due to a high heterogeneity
among these seven studies, their effect sizes were not
combined quantitatively in a meta-analysis. The studies
were not comparable because they utilised different classi-
fications of anxiety disorders (either anxiety alone or co-
morbid anxiety and depression) and cannabis use (either
use vs. no use or use with vs. without cannabis use disor-
ders, such as dependence or abuse/harmful use). There-
fore, it is not surprising that the effect sizes in the seven
studies were highly inconsistent and did not suggest any
general trend towards presence or absence of a relation-
ship between anxiety and cannabis use [10].
The aim of the current study was to quantitatively assess
the relationship between anxiety and cannabis use by
means of a systematic literature review followed up by a
quantitative meta-analysis. In contrast to Moore and col-
leagues [10], our aim was to include not only the large lon-
gitudinal studies but also smaller cross-sectional studies.
The reasons for including such studies were to improve
the statistical power of meta-analysis and to perform
the analyses on subgroups of more homogenous studies.
Specifically, our aim was to conduct the statistical meta-
analysis on subgroups of studies based on similar classifi-
cation of anxiety disorders (anxiety alone vs. comorbid
anxiety and depression) and cannabis use (use vs. no use
or use with vs. without cannabis use disorders). Finally, it
was of interest to find out if an adequate volume of studies
exists to test the direction of the main relationship. Specif-
ically, our aim was to compute the odds for cannabis use
at follow-up in cohorts with baseline anxiety and the odds
for anxiety at follow-up in cohorts with baseline cannabis
use.
It was hypothesised that a positive relationship exists be-
tween anxiety disorders and cannabis use (particularly with
cannabis use disorders) based on the positive relationships
between particularly heavy cannabis use and other psychi-
atric diagnoses (such as psychosis and depression). We ex-
pected that some evidence for the direction of such a
relationship could emerge from the analysis of prospective
studies. Specifically, we could establish which baseline
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higher odds of the other condition at follow-up. Further-
more, it was expected that the association between anxiety
and cannabis use (or cannabis use disorders) would be
lower (or even absent) in studies with effect sizes adjusted
for confounding factors, such as other substance use, other
psychiatric comorbidity, and demographics (age, gender),
compared to studies with unadjusted effect sizes. Finally, it
cannot be ruled out that the use of more advanced quanti-
tative models to establish prevalence of comorbid condi-
tions had some influence on the effect sizes reported in
primary studies over time. Thus, we expected that there
would be a negative relationship between effect sizes and
the date of publication of studies (regardless of when the
data were collected). Specifically, we hypothesised that the
effect sizes would be adjusted for more factors using more
complex statistical models (and thus be lower) in the
newer than in the older studies.
Methods
Systematic literature search
A systematic literature search was conducted in March
2013, according to the steps depicted in Table 1.
A total of N = 267 sources identified during the search
(Table 1) were assessed and N = 218 studies were ex-
cluded (the reasons for exclusion are summarised in the
Additional file 1: Table S1).
Study selection
The summary of the study selection procedure and ex-
clusion criteria are shown in the PRISMA flowchart
[25], Figure 1.
Of N = 267 sources, N = 49 studies were retrieved and
assessed in full-length. All these studies and, if applic-
able, the reasons for their exclusion are listed in the
Additional file 1: Table S2. A total of N = 31 studies were
selected for inclusion in the final analysis. Studies were
included if they reported:
(1) Data based on samples from a non-institutionalised,
general population;
(2) Anxiety diagnoses (with or without comorbid
depression), based on DSM/ICD diagnostic criteria,Table 1 Details of the systematic literature search (all searche
Search Search terms
Search 1 N = 131 Subject OR Title (cannabis or marijuana or marihuana) A
or “anxiety disorder” or anxiety) NOT (mouse or mice or
Search 2 N = 168 Subject OR Title (cannabis or marijuana or marihuana) A
or “anxiety disorder” or anxiety) AND Keyword (misus* o
or "harmful usage") NOT (mouse or mice or rat or rats)
N = 256 Total N from both searches excluding duplicates
Note: Additional N = 11 studies were obtained from other meta-analyses being con
and from the bibliography of Moore et al. [10].
N = number of sources identified during each search.and/or anxiety severity score, based on standardised
scales, in cannabis users/non-users or cannabis
users with/without cannabis use disorder (CUD).
CUD was defined as dependence and/or abuse/
harmful use according to DSM/ICD criteria;
(3) Cannabis use/no use (or cannabis use with/without
CUD) in cases with anxiety/no anxiety;
(4) Odds ratios, ORs, and their 95% confidence intervals,






ducted b anxiety/no anxiety in cannabis users/non-users
or cannabis users with/without CUD or
 cannabis use/no use or cannabis use with/
without CUD in cases with anxiety/no anxiety;(5) Data sufficient to compute other effect sizes, that
were later converted into OR, such as the
standardised mean difference (Cohen’s d), based on
means, SD, and N of severity of anxiety scores in
cannabis users/non-users (or cannabis users with/
without CUD).
Studies were excluded if they:
(1) Did not report data from healthy non-users;
(2) Reported data from samples seeking treatment for
CUD and/or with a high comorbidity of other-
substance use and/or other concurrent psychiatric
disorders than anxiety and depression;
(3) Reported inadequate data to compute any effect
size (unless the authors provided additional data).
Data extraction
The data from N = 31 studies were extracted/double-
checked for consistency by both authors.
The characteristics of all N = 31 studies and the effect
size data from these studies are listed in Tables 2 and 3.
To maintain a high consistency of results the following
data extraction rules were used:
(1) Only the most conservative estimates of ORs were
extracted (i.e. the ORs adjusted for as many
confounders as possible). If data based on the same
cases were presented in more than one study thenducted in English with no language restrictions)
Databases and timeframes
bject OR Title (“affective disorder”
rats)
PsycInfo (1806-March 2013)
bject OR Title (“affective disorder”
or depend* or "harmful use"
Medline (1950-March 2013)





N=256 records from 
database searching 




N=49 full-text articles 
assessed by LTL/KKK
N=18/49 (37%) articles 
excluded:
N=6 Cannabis vs. anxiety 
comparison not shown
N=3 Inadequate data to 
compute the odds ratio
N=3 High comorbidity with 
other substances
N=2 Anxiety diagnosis or 
severity of anxiety missing
N=2 No new data (data 
from studies already in 
analysis)
N=1 Healthy non-users 
missing
N=1 Non-users missing
N=31 studies included 
in the quantitative 
meta-analysis
N=267 records after duplicates removed
N=218 excluded
N=11 studies identified through 
hand search
Figure 1 Selection of studies and exclusion criteria.
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for the final analysis;
(2) Data based on the longest possible time-spans
(lifetime) were extracted;
(3) Data based on the heaviest use and/or cannabis
dependence were extracted;
(4) Consistent estimates were extracted to combine
ORs from different studies using data from the
same cases (e.g. lifetime PTSD and lifetime panic
disorder from two NCS-R studies, see Table 3);
(5) As many types of anxiety disorders as possible were
included if ORs for individual anxiety disorders were
reported separately for different groups of cases.
Meta-analysis
The mathematical details of meta-analysis used in the
current study are explained in the Additional file 1. The
analysis was conducted on the Comprehensive Meta-
Analysis software (CMA 2.2; Biostat, USA) using the
random-effects model [57]. This model was chosen be-
cause it was expected that only a random sample of all
studies (published or unpublished) on the topic was lo-
cated during the systematic literature search, that the effect
sizes would differ due to methodological heterogeneity
among studies in this analysis, and that the current results
could be generalisable to a wider general population.In the first step of the analysis, a common effect size,
the odds ratio (OR) and its 95% confidence interval
(95% CI), were either computed by the authors or ex-
tracted from the N = 31 studies (Table 3). Subsequently,
all effect sizes were weighted based on the inverse-
variance method also known as the method of moments
or DerSimonian and Laird method [58]. According to
this method the weight is defined as the inverse of the
sum of within-study and between-study variance. Com-
pared to larger studies, the smaller-N studies usually
have high variability of scores (high variance, low preci-
sion) and thus low weight. Consequently, such small stud-
ies have little influence on the overall mean weighted OR
and vice versa.
The overall mean weighted OR was computed by divid-
ing the sum of the product of weights and log ORs in each
study by the sum of all weights. An OR < 1 indicated that
cannabis use (or CUD) is associated with lower prevalence
of anxiety and vice versa. The magnitude of OR was inter-
preted as follows [59]:
 OR > 1: 1.5 (small), 2.5 (moderate), ≥4 (large)
 OR < 1: 0.67 (small), 0.4 (moderate), ≤0.25 (large)
 OR = 1 and/or 95% CI crossing the line of no effect
(OR = 1): no association between cannabis use (or
CUD) and anxiety.
Table 2 Characteristics of N = 31 studies included in the current meta-analysis

























Probability CIDI DSM-III-R AD (current) – CIDI DSM-III-R Use (past month);
CD (lifetime)
–
Beard et al., 2006;
NoRMHS, Australia [27]
Longitudinal 9191 (1013) General
population
Random CIDI ICD-10 PD, SP, OCD
(at T1)
15% (at T1) CIDI ICD-10 CUD (at T0) CUD 3% (at T0)
Brook et al., 1998;
Upstate NY, USA [28]




Random DISC DSM-III-R SA, OAD, SAD
(at T4)
– DISC DSM-III-R Never- ≥ weekly
(at T3)
Use (at T3): 56%
never 9% ≥
weekly
Brook et al., 2001;
Colombia [29]
Longitudinal 2226 Adolescents Random HSC AD (at T1, T2) – Interview Non-regular- regular
(≥monthly; lifetime)
–
Buckner et al., 2008;
Oregon, USA [30]




Random K-SADS DSM-III-R SAD (at T1) 2% (at T1) LIFE, SCID-I/
NP DSM-IV
CD (at T4) CD 6% (at T4)
Buckner & Schmidt,
2008; USA [31]
Cross-sectional 337 (214) Undergraduate
students









Buckner et al., 2012;
USA [32]
Cross-sectional 343 (200) Adult tobacco
smokers
Random SIAS Equivalent to
SAD





Cascone et al., 2011;
Switzerland [33]













Chabrol et al., 2005;
France [34]
Cross-sectional 212 High school
and college
students
Random STAI A State anxiety – Questionnaire
DSM-IV
Past 6 months:
None- > daily; CD
46% none 23% >
daily
Chabrol et al., 2008;
France [35]
Cross-sectional 248 High school
students

















Interview None- daily (past
12 months)
–










Crum et al., 1993;
ECA, USA [38]
Longitudinal 18572 (577) General
population




DIS No use- use ≥6×
(past 12 months)














CIDI DSM-IV Past 12 months:
No use- use ≥5×;
CD
Past 12 months:












AMD (at 24) 21% (at 24) Interview None- weekly+































CIDI ICD-10 GAD, SAD, PD,
AP (past 12
months at 29)












Longitudinal 1265 (927) Adolescents
(16 years)
Stratified DISC/DIS DSM-III-R GAD, OAD, SA
(at 15–16)
















Lamers et al., 2006;
USA [44]
Cross-sectional 41 (30) General
population







Low et al., 2008;
USA [45]
Cross-sectional 632 Adolescents in
primary care





















CA + CD (lifetime) –
McGee et al., 2000;
DMHDS, New
Zealand [47]
Longitudinal 1037 (891) Adolescents
(at 15)
Convenience DISC DSM-III Internalising
disorders (AMD;
at 15)
12% (at 15) Interview None- use ≥1
(past 12 months)
14% users (at 15)
NPMS, UK; appendix,
Moore et al., 2007 [10]
Longitudinal 8580 (1578) Adults (at
16–74)




16% users 2% CD








CIS-R ≥ 12 at 21 AMD (at 21) 16% (at 21) Interview None- < weekly




Roberts et al., 2007;
TH2K, USA [49]





DISC DSM-IV CUD (past 12
months)
3% CUD (past 12
months)








CIS-R > 11 AMD (at 15–17) – Interview, CIDI
DSM-IV




24 who used at
15-17
van der Pol et al., 2013;
CanDep + NEMESIS-2,
Netherlands [51]















CIDI DSM-IV No CD (group N2;
none or <3×/week
use)- CD (D+; use
≥3×/week) (past
12 months)
16% CD (past 12
months)































Table 2 Characteristics of N = 31 studies included in the current meta-analysis (Continued)
Wittchen et al., 2007;
EDSP, Germany [53]

































Notes: All studies included males and females of any race. Abbreviations: AD = anxiety disorder; ADAD = Adolescent Drug Abuse Diagnosis (based on Addiction Severity Index); AMD = anxiety + depression;
AP = agoraphobia; AUDADIS = Alcohol Use Disorders and Associated Disabilities Interview Schedule; BAI = Beck Anxiety Inventory; CA = cannabis abuse; CAMH = Centre for Addiction and Mental Health Monitor survey,
Canada; CanDep = the Dutch Cannabis Dependence Study, Netherlands; CD = cannabis dependence; CHDS = Christchurch Health and Development Study, New Zealand; CIDI = Composite International Diagnostic
Interview; CIS-R = Clinical Interview Schedule- Revised; CSHS = Colorado Social Health Survey, USA; CUD = cannabis use disorder (abuse/harmful use and/or dependence); D + = frequent cannabis users with dependence
in CanDep study; DIS = Diagnostic Interview Schedule; DISC = Diagnostic Interview Schedule for Children; DMHDS =Dunedin Multidisciplinary Health and Development Study, Dunedin, New Zealand; ECA = Epidemiological
Catchment Area program, USA; EDSP = Early Developmental Stages of Psychopathology study, Germany; GAD= generalized anxiety disorder; GHQ-12 = General Health Questionnaire (12 items); HSC = Hopkins Symptom
Checklist; K-SADS = Schedule for Affective Disorders and Schizophrenia for School-Age Children; LIFE = Longitudinal Interval Follow-up Evaluation; MUSP =Mater University Study of Pregnancy, Brisbane, Australia; NCS =
National Comorbidity Survey, USA; NCS-R = National Comorbidity Survey- Replication, USA; NEMESIS/NEMESIS-2 = Netherlands Mental Health Survey and Incidence Study (study 1: 1996–1999 and study 2: 2007–2009),
N2 = NEMESIS-2 cases; Netherlands; NESARC =National Epidemiological Survey on Alcohol and Related Conditions, USA; NoRMHS = the Northern Rivers Mental Health Study, New South Wales, Australia; NPMS = the British
National Psychiatric Morbidity Survey, UK; NSMHWB=National Survey of Mental Health and Well-Being, all states, Australia; OAD = overanxious disorder; OCD = obsessive compulsive disorder; PA = panic attacks; PD = panic
disorder; PRIME-MD = Primary Care Evaluation of Mental Disorders; PTSD = post-traumatic stress disorder; SA = separation anxiety; SAD = social anxiety disorder/social phobia; SCID-I/NP = Structured Clinical Interview for DSM-IV,
non-patient version; SIAS = Social Interaction Anxiety Scale; SP = specific phobias; STAI = State-Trait Anxiety Inventory; STAI-Y = STAI for Youth; STAI-Y A = STAI state anxiety subscale; STAI-Y B = STAI trait anxiety subscale;
T = specific wave of data collection in longitudinal studies; TH2K = Teen Health 2000 Study, Houston, USA; VAHCS = Victorian Adolescent Health Cohort Study, Victoria, Australia; YASR = Young Adult Self-Report.
*Cross-sectional was chosen if the results were obtained from one data set (even if the study was longitudinal), longitudinal refers to studies that show data at different time points (waves).
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using a Q-statistic and an I2 index [60]. The Q-statistic
tests the null-hypothesis that Q = 0 meaning that there
is homogeneity in effect sizes among studies included
in the analysis. The I2 index expresses the Q-statistic
on a 0-100% scale (I2 = 100% × (Q-df )/Q) using df = k-1
(k = number of studies) and can be interpreted as the
variability in effect sizes due to real differences among
studies (as opposed to differences due to chance alone).
The interpretation criteria for I2 are: 25% (little hetero-
geneity), 50% (moderate heterogeneity), and 75% (high
heterogeneity) [60].
Three separate meta-analyses were performed on the
data reported in Table 3:
 anxiety/no anxiety vs. cannabis use/no use,
 anxiety/no anxiety vs. CUD/no CUD (or no use),
 anxiety + depression/no diagnosis vs. cannabis use/
no use.
Sensitivity and moderator analyses
The stability of the overall mean weighted OR in each
analysis was investigated using one-study removed and
cumulative analyses. These analyses show how the over-
all mean weighted OR changes if one study at a time is
removed from all other studies or studies are added cu-
mulatively over time. The moderator analyses (univari-
ate meta-regression and subgroup analysis) were used
to investigate the direction of the relationship between
anxiety and cannabis use and the influence of sys-
tematic differences among studies on the overall mean
weighted OR.
Publication bias analyses
Publication bias refers to an overestimation of the over-
all mean weighted effect size in meta-analysis due to in-
clusion of studies based on large sample sizes and/or
large effect sizes [57]. Such studies are more likely to be
published and thus are easier to locate during a system-
atic literature search. In contrast, studies with smaller
samples and/or small (often not statistically significant)
effect sizes are either not published at all or published in
smaller (often non-English language) journals that are
not listed on major databases [57].
Publication bias in the current study was assessed
using methods available in CMA, which are described in
detail in the Additional file 1. The theoretical number of
null-studies (with OR = 1) required to remove the statis-
tical significance of the overall mean weighted OR was
computed using Rosenthal’s Fail-Safe N [61]. Further-
more, the symmetry in a funnel plot of OR (on a loga-
rithmic scale) vs. SEM [62] was assessed using the Duval
and Tweedie’s Trim-and-Fill analysis [63]. Finally, the
Begg and Mazumdar Rank Order Correlation (Kendall’stau b) [64] and Egger’s regression [65] were used to in-
vestigate the relationship between the standardised OR
and SEM or 1/SEM in each study, respectively. According
to these methods, a systematic publication bias might be
present in meta-analysis if the Fail-Safe N is small and
smaller studies differ systematically (significantly) from the
larger studies (funnel plot asymmetrical, correlation statis-
tically significant, and regression intercept significantly dif-
ferent from zero) [57].
Results
According to three separate meta-analyses summarised
in Table 4, there was a small positive association
between
 anxiety and cannabis use (OR = 1.24, 95% CI:
1.06-1.45; Figure 2),
 anxiety and cannabis use disorders (CUD; OR = 1.68,
95% CI: 1.23-2.31; Figure 3), and
 anxiety + depression and cannabis use (OR = 1.68,
95% CI: 1.17-2.40; Figure 4).
Thus, those with various anxiety disorders and concur-
rent anxiety + depression were more likely to use cannabis
or had a CUD (dependence and/or abuse/harmful use)
compared to those without anxiety disorders.
There was little evidence for a systematic publication
bias because Fail-Safe Ns were high (N = 17 to 105),
between 3 to 8 unpublished studies were needed for
every study in the analysis to reduce the overall mean
weighted OR to 1 (Table 4), and the funnel plots were
symmetrical around the overall mean weighted OR
(Figures 2, 3 and 4).
One-study removed analysis showed that the results
of two analyses (anxiety vs. cannabis use and anxiety vs.
CUD) were stable and not dependent on any one study
alone (Table 4). Specifically, no study was able to elim-
inate the significant associations when removed from
the analysis one at a time (Additional file 1: Figure S1).
However, the results of the anxiety + depression vs. can-
nabis use analysis were dependent on one study [36].
Without this study there was only a non-significant
trend (p = .058) towards a positive association between
anxiety + depression and cannabis use (Table 4; Additional
file 1: Figure S1).
The cumulative analysis showed that the significant
and positive association between anxiety and cannabis
use emerged as studies published in 1998–2013 were
added to the overall analysis one at a time (Table 4).
The results indicate that the overall effect size was
always small as new studies were added to all pre-
vious studies (Additional file 1: Figure S2). Similar
conclusion can be drawn regarding the small, posi-
tive, and significant association between anxiety and
Table 3 Odds ratios (OR) for anxiety (or anxiety + depression) vs. no disorder in cannabis users vs. non-users (or in cannabis users with CUD vs. no CUD) in
N = 31 studies
Study/Name (Part 1:
anxiety diagnoses)











Agosti et al., 2002; NCS, USA
[26]
Current AD in lifetime CD who
used within past month vs. no CD
2.6 (1.5-4.5) Text p. 646 No information
Beard et al., 2006; NoRMHS,
Australia [27]1
T0 CUD (vs. no CUD) to T1 AD .78 (.18-3.30) Table three Unadjusted (comorbidity with
other diagnoses possible)
Brook et al., 1998; Upstate NY,
USA [28]
T4 AD to T3 use vs. no use 1.16 (1.00-1.35) Table two Demographics, prior AD
Brook et al., 2001; Columbia
[29]2
T1 AD to T2 regular vs. non-
regular use
.94 (.86-1.03) Table one Demographics, cannabis use at T1
T1 regular vs. non-regular use to
T2 AD
1.48 (1.09-2.01) Table two Demographics, AD at T1
Combined: AD or regular use:
T1 vs. T2
1.18 (.94-1.48)
Buckner et al., 2008; Oregon,
USA [30]
T1 SAD to T4 CD vs. no CD 4.88 (1.43-16.64) Text p. 235 Gender, T1 anxiety, conduct,
mood, alcohol use disorders, T1
CUD excluded
Cascone et al., 2011;
Switzerland [33]
Past 12 months CD (vs. no CD)
predicted with STAI-Y B
1.02 (.97-1.08) Table five Withdrawal coping, social
problems, recruitment context
Cougle et al., 2011; NCS-R,
USA [37]3
Lifetime: PTSD to use vs. no use 2.45 (1.70-3.52) Table one Demographics, lifetime alcohol/
nicotine dependence/abuse
Crum et al., 1993; ECA, USA
[38]4
Past 12 months: OCD to use vs.
no use
1.54 (.78-3.04) Table one Excluded past or baseline OCD
cases
Degenhardt et al., 2001;
NSMHWB, Australia [39]
Past 12 months: AD to use vs. no
use
Past 12 months: AD to CD vs. no
use
.88 (.60-1.29) 1.40 (.84-2.37) Table four Demographics, other substance
use, neuroticism
Degenhardt et al., 2013;
VAHCS, Australia [41]
AD at 29 to ≥ weekly vs. no use
at 15-29
AD at 29 to CD at 29 vs. no CD 3.2 (1.1-9.2) 2.2 (1.1-4.4) Table one, three Demographics, alcohol/substance
use at 29, adolescent anxiety/
depression
Fergusson et al., 1996; CHDS,
New Zealand [42]
AD at 16 to use vs. no use at 15 1.2 (.5-2.8) Table three Demographics, substance use
and dependence, anxiety/
depression, other mental health
problems at 15
Low et al., 2008; USA [45] Past 6 months: CA (vs. no CA) to
AD
1.4 (.4-4.7) Table four Demographics, sampling site,
depression
Martins & Gorelick, 2011;
NESARC, USA [46]


















Table 3 Odds ratios (OR) for anxiety (or anxiety + depression) vs. no disorder in cannabis users vs. non-users (or in cannabis users with CUD vs. no CUD) in
N = 31 studies (Continued)
Roberts et al., 2007; TH2K,
USA [49]
Past 12 months: AD to CUD vs. no
CUD
.9 (.4-2.1) Table six Concurrent (past 12 months)
mood, conduct, ADHD disorders;
alcohol, other substance abuse/
dependence
van der Pol et al., 2013;
CanDep + NEMESIS-2,
Netherlands [51]
Past 12 months: AD to CD (vs.
no/non-frequent use) (D + vs. N2
groups)
1.12 (.48-2.63) Table two; Authors Demographics, childhood
adversity, tobacco (past month),
frequent alcohol, cocaine, ecstasy
use (past 12 months)
van Laar et al., 2007; NEMESIS,
Netherlands [52]
AD (T0-T2) to T0 use vs. no use 1.18 (.71-1.97) Table four Demographics, neuroticism,
childhood trauma, lifetime:
alcohol, other SUDs, psychotic
symptoms, AD
Wittchen et al., 2007; EDSP,
Germany [53]
Lifetime use vs. no use to T0 AD Lifetime CUD vs. no CUD to T0 AD 1.5 (1.1-2.1) 1.7 (1.1-2.5) Table four Gender
Zvolensky et al., 2006; CSHS,
USA [54]
Lifetime: use vs. no use to PA Lifetime: CD vs. no CD to PA .89 (.63-1.30) 2.1 (1.1-4.3) Text p. 482 Demographics, other substance
use
Zvolensky et al., 2010; NCS-R,
USA [55]3
Lifetime: PD to use vs. no use 1.70 (1.33-2.17) Table one Demographics, lifetime alcohol,
nicotine, illicit substance abuse/
dependence
NCS-R combined3 Lifetime: PTSD + PD to use vs. no
use
2.04 (1.50-2.78)

















Location in study Scale (study exclusionarycriteria)







.81 (.50-1.33) Table one SIAS (none)






1.05 (.62-1.80) Table one; Authors SIAS (high-risk suicidal behaviour,
psychotic)







38.1 (9.8); 44 (past 6 months) 1.36 (.83-2.22) 1.61 (.84-3.07) Table two Table
three
STAI A (none)







1.94 (1.14-3.30) Table one STAI A (none)




























Table 3 Odds ratios (OR) for anxiety (or anxiety + depression) vs. no disorder in cannabis users vs. non-users (or in cannabis users with CUD vs. no CUD) in
N = 31 studies (Continued)
Study/Name (Part 3:
anxiety + depression, AMD)
Cannabis use vs. no use CUD vs. no CUD (or no use) OR (95% CI) AMD/





Location in study OR adjusted for
Cheung et al., 2010; CAMH,
Canada [36]
Past 12 months: AMD to daily
use vs. no use
2.05 (1.18-2.93) Table two Demographics, alcohol misuse
Degenhardt et al., 2010;
VAHCS, Australia [40]6
AMD at 24 (wave 8) to weekly +
use vs. no use past 6 months at
15–17 (wave 1–6)
.88 (.55-1.40) Table two Demographics, adolescent: AMD,
alcohol, nicotine use
Hayatbakhsh et al., 2007;
MUSP, Australia [43]
AMD at 21 to frequent (past
month) vs. never used drugs
(lifetime)
2.1 (1.1-4.0) Table four Demographics, no other illicit
drugs, maternal and adolescent:
AMD, alcohol, nicotine use
McGee et al., 2000; DMHDS,
New Zealand [47]7
Internalising disorders at 15 to
use vs. no use past 12 months at
15
2.45 (1.41-4.25) Table five Unadjusted (adjusted OR could
not be used because 95% CI
were not reported)
NPMS, UK; appendix, Moore
et al., 2007 [10]
AMD (CIS-R ≥ 12) to ever use vs.
no use
AMD (CIS-R ≥ 12) to CD vs. no CD .8 (.4-1.6) .9 (.2-3.6) p. IV Excluded if baseline CIS-R ≥ 12,
demographics, other drugs,
alcohol, nicotine use
Patton et al., 2002; VAHCS,
Australia [48]6
AMD (CIS-R ≥ 12) at 21 (wave 7)
to < weekly use vs. no use past 6
months at 15–17 (wave 1–6)
1.4 (.94-2.0) Table three AMD at 15–17, alcohol use,
parental demographics
Swift et al., 2008; VAHCS,
Australia [50]6
Weekly + use vs. no use (past 12
months at 24, wave 8, who used
cannabis at 15–17, waves 1–6) to
AMD (CIS-R > 11) at 15–17 (at 3/6
waves of wave 1–6)
CD vs. no CD (past 12 months at
24, wave 8, who used cannabis
at 15–17, waves 1–6) to AMD
(CIS-R> 11) at 15–17 (at 3/6
waves of wave 1–6)
2.0 (1.0-3.8) 1.4 (.71-2.9) Table four Demographics, adolescent:
maximum level of cannabis use,
nicotine and alcohol use,
antisocial behaviour
VAHCS combined6 AMD at 15–24 to at least <
weekly use at 15–17 (vs. no use)
1.35 (.80-2.27)
Notes: For abbreviations refer to Table 2.
1The OR was computed based on the following N of cases in the ‘Anxiety’ column and ‘Baseline No Diagnosis’ and ‘Cannabis Diagnosis’ rows reported in Table three of the article: N = 2 (CUD/anxiety), N = 46 (CUD/no
anxiety), N = 51 (no CUD/anxiety), N = 914 (no CUD/no anxiety).
2The two ORs were combined according to the formulae for combining dependent effect sizes shown in the Additional file 1.
3Both studies reported ORs based on the same number of cases from the same study (NCS-R). It was assumed that both studies were dependent (same cases might have been used to compute the ORs in both
studies). Thus, both ORs were combined into one common OR that was used in all subsequent analyses using the formulae shown in the Additional file 1.
4The OR was computed based on the following N of cases in the ‘Cases’ (OCD) vs. ‘Non-cases’ columns and ‘Use of marijuana only’ and ‘No drug use’ rows reported in Table one of the article: N = 12 (use/anxiety),
N = 42 (use/no anxiety), N = 82 (no use/anxiety), N = 441 (no use/no anxiety). The risk ratio (RR), adjusted for confounders, was also reported in the study (Table two). However, RR and OR are not equivalent [56] and
thus unadjusted OR is computed here which is more conservative than the RR in Table two of the study (RR = 2.1, 95% CI: 1.0-4.5).
5The STAI A scores reported separately for girls and boys were combined into one score in each of the three groups- non-users, users, and users with CUD using the formulae shown in the Additional file 1. The ORs in
this study were computed based on these combined scores since all other studies in the current analysis reported anxiety scores in both genders combined rather than separately.
6The ORs in studies utilising VAHCS data from waves 1–8 were combined according to the formulae for combining dependent effect sizes shown in the Additional file 1.
7The OR was computed based on the following N of cases in the ‘Cannabis use at age 15’ and ‘Mental disorder- Internal (anxiety and depression)’ columns reported in Table five of the article: N = 20 (use/internal),
N = 62 (use/no disorder), N = 84 (no use/internal), N = 637 (no use/no disorder).
*The standardised mean difference (Cohen’s d) was computed for user – non-user or CUD – non-user groups in all studies in Part 2 of this table. This effect size was then converted into OR using the formulae shown


















Table 4 Results of three random-effects meta-analyses on the association between anxiety vs. cannabis use or CUD and anxiety + depression vs. cannabis use
Anxiety vs. use/no use
N = 15 (Figure 2)
Anxiety vs. CUD/no CUD
(or no use) N = 13 (Figure 3)
Anxiety + depression vs. use/
no use N = 5 (Figure 4)
Overall mean weighted OR OR (95% CI) ptwo-tailed 1.24 (1.06-1.45) .006* 1.68 (1.23-2.31) .001* 1.68 (1.17-2.40) .004*













(Additional file 1: Figure S1)
Which studies, removed one at a time from the analysis,
remove the significance of the overall mean weighted OR?
None None Cheung et al., 2010 [36]
Cumulative analysis (1993 to 2013)
(Additional file 1: Figure S2)
Which studies, added to all previous studies one at a time,
remove the significance of the overall mean weighted OR?
Crum et al., 1993 [38];
Fergusson et al., 1996 [42]
Degenhardt et al., 2001 [39] NPMS, 2007 [10]
Rosenthal’s Fail-safe N for p > .05 N studies needed to remove the significance of the overall
mean weighted OR (N studies missing for every study in
meta-analysis needed to remove the significance of the







Duval and Tweedie’s Trim-and-Fill
analysis
Funnel plot symmetrical? N studies missing on either side
of the overall mean weighted OR
YES YES YES
N=0 N=0 N=0
Begg and Mazumdar Rank Order
Correlation
τ .13 -.19 -.30
ptwo-tailed .488 .360 .462
Egger’s regression intercept .25 1.73 −4.05
ptwo-tailed .748 .005* .415
Note: Figure numbers refer to forest plots and funnel plots for each analysis (Figures S1 and S2 can be found in the Additional file 1).



















Study name Statistics for each study Odds ratio and 95% CI
Odds Lower Upper 
ratio limit limit p-Value
Crum et al. 1993 [38] 1.54 0.78 3.04 0.218
Fergusson et al. 1996 [42] 1.20 0.51 2.84 0.678
Brook et al. 1998 [28] 1.16 1.00 1.35 0.053
Brook et al. 2001 [29] combined 1.18 0.94 1.48 0.153
Degenhardt et al. 2001 [39] 0.88 0.60 1.29 0.513
Chabrol et al. 2005 [34] 1.36 0.83 2.22 0.222
Lamers et al. 2006 [44] 0.55 0.15 2.03 0.368
Zvolensky et al. 2006 [54] 0.89 0.62 1.28 0.528
van Laar et al. 2007 [52] 1.18 0.71 1.97 0.525
Wittchen et al. 2007 [53] 1.50 1.09 2.07 0.014
Buckner & Schmidt 2008 [31] 0.81 0.50 1.33 0.409
Chabrol et al. 2008 [35] 1.94 1.14 3.30 0.015
NCS-R 2010 [37,55] combined 2.04 1.50 2.78 0.000
Buckner et al. 2012 [32] 1.05 0.62 1.80 0.853
Degenhardt et al. 2013 [41] 3.20 1.11 9.25 0.032
1.24 1.06 1.45 0.006
0.1 0.2 0.5 1 2 5 10
- association + association

















Funnel Plot of Standard Error by Log odds ratio
Figure 2 Random-effects meta-analysis of N = 15 studies on anxiety vs. cannabis use/no use. Notes: The forest plot (top) shows the effect
size (OR) in each study, the weight of each study (size of the box), and the 95% CI (the horizontal line through each box). The overall mean
weighted OR is depicted as the centre of the diamond and its horizontal edges are the 95% CI. Since the diamond did not cross the line of no
effect (OR=1), there was an overall positive association between anxiety and cannabis use in N=15 studies (overall mean weighted OR=1.24,
95% CI: 1.06-1.45). The funnel plot (bottom) shows the distribution of the individual effect sizes around the overall mean weighted OR (unfilled
diamond). The trim-and-fill analysis revealed that the plot was symmetrical (the recomputed overall mean weighted OR depicted as the filled
diamond overlaps with the unfilled diamond) suggesting that there was little evidence for a publication bias in the current analysis.
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http://www.biomedcentral.com/1471-244X/14/136CUD that emerged in studies published in 2002–2013
and remained consistently small. In contrast, adding
the results of the NPMS study [10] either eliminated
or reduced the positive association between anxiety +
depression vs. cannabis use in studies published in
2000–2010 (Additional file 1: Figure S2).
As expected there was a moderate-high heterogeneity
among the effect sizes in the three meta-analyses
(Table 4). Specifically, according to the I2 index, between
50-78% of variability in ORs was due to real differences
among studies rather than chance. The inspection of
study characteristics in Tables 2 and 3 revealed that suchheterogeneity was probably due to two hypothesised sys-
tematic differences among studies:
(1) OR adjustment- in some studies ORs were controlled
for confounders, such as other substance use, other
substance use disorders, past anxiety, other psychiatric
illness, and demographics (age, gender) while in other
studies no statistical adjustment of ORs was used,
(2) year of publication- more recent studies might have
applied more complex statistical modelling techniques
to adjust ORs compared to the older studies regardless
of when the data were actually collected.
Study name Statistics for each study Odds ratio and 95% CI
Odds Lower Upper 
ratio limit limit p-Value
Degenhardt et al. 2001 [39] 1.40 0.83 2.35 0.204
Agosti et al. 2002 [26] 2.60 1.50 4.50 0.001
Chabrol et al. 2005 [34] 1.61 0.84 3.07 0.151
Beard et al. 2006 [27] 0.78 0.18 3.30 0.735
Zvolensky et al. 2006 [54] 2.10 1.06 4.15 0.033
Roberts et al. 2007 [49] 0.90 0.39 2.06 0.803
Wittchen et al. 2007 [53] 1.70 1.13 2.56 0.011
Buckner et al. 2008 [30] 4.88 1.43 16.65 0.011
Low et al. 2008 [45] 1.40 0.41 4.80 0.592
Cascone et al. 2011 [33] 1.02 0.97 1.08 0.470
Martins & Gorelick 2011 [46] 3.20 1.98 5.16 0.000
Degenhardt et al. 2013 [41] 2.20 1.10 4.40 0.026
van der Pol et al. 2013 [51] 1.12 0.48 2.62 0.794
1.68 1.23 2.31 0.001
0.1 0.2 0.5 1 2 5 10
- association + association

















Funnel Plot of Standard Error by Log odds ratio
Figure 3 Random-effects meta-analysis of N = 13 studies on anxiety vs. cannabis use disorder (CUD)/no CUD (or no use). Notes: The
forest plot (top) shows that there was an overall positive association between anxiety and CUD in N=13 studies (overall mean weighted OR=1.68,
95% CI: 1.23-2.31). The funnel plot (bottom) was symmetrical suggesting that there was little evidence for a publication bias in the current analysis.
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http://www.biomedcentral.com/1471-244X/14/136One additional systematic difference among studies
emerged only after the data were extracted from all studies
(Tables 2 and 3):
(3) diagnosis of anxiety- in some studies cases had
clinical diagnoses (DSM/ICD-based) while in other
studies only the severity of anxiety scores on
standardised instruments were reported (these studies
were classified as having ‘non-clinical diagnoses’ for
the purposes of the current analysis).
Taking into account these differences among studies, two
types of moderator analyses were performed: subgroup
analyses to compare the overall mean weighted ORs insubgroups of studies above and a univariate meta-
regression to investigate if the year of publication could
predict weighted ORs in all studies. Moderator analyses
were not performed on studies with anxiety + depression
because there was only one such study with unadjusted OR
and one study with a clinical diagnosis of anxiety +
depression.
According to the subgroup analyses, the majority of
studies included in the current meta-analysis reported
ORs adjusted for potential confounders (Table 5). Inter-
estingly, the small positive association between anxiety
and cannabis use (or CUD) was still present even after the
adjustment for such confounders (Table 5; Additional
file 1: Figure S3). Therefore, it appears that the higher
Study name Statistics for each study Odds ratio and 95% CI
Odds Lower Upper 
ratio limit limit p-Value
McGee et al. 2000 [47] 2.45 1.41 4.25 0.002
Hayatbakhsh et al. 2007 [43] 2.10 1.10 4.00 0.024
NPMS 2007 [10] 0.80 0.40 1.60 0.528
Cheung et al. 2010 [36] 2.05 1.30 3.23 0.002
VAHCS 2010 [40,48,50] combined 1.35 0.80 2.27 0.255
1.68 1.17 2.40 0.004
0.1 0.2 0.5 1 2 5 10
- association + association

















Funnel Plot of Standard Error by Log odds ratio
Figure 4 Random-effects meta-analysis of N = 5 studies on anxiety + depression vs. cannabis use/no use. Notes: The forest plot (top)
shows that there was an overall positive association between anxiety+depression and cannabis use in N=5 studies (overall mean weighted
OR=1.68, 95% CI: 1.17-2.40). The funnel plot (bottom) was symmetrical suggesting that there was little evidence for a publication bias in the
current analysis.
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http://www.biomedcentral.com/1471-244X/14/136odds for anxiety in cannabis users (with or without
CUD) are not exclusively due to the effects of other
substances, psychiatric illnesses, or demographics.
There were too few studies (N = 3) to reliably investi-
gate these associations in studies with ORs unadjusted
for confounders. There was a trend for a positive associ-
ation between anxiety vs. CUD in N = 3 studies with un-
adjusted ORs (Table 5; Additional file 1: Figure S3).
Furthermore, the majority of current studies included
cases with clinical diagnoses of anxiety according to DSM
and/or ICD diagnostic systems. The small positive associ-
ation between anxiety and cannabis use (or CUD) was
present in the subgroups of studies with clinical diagnoses
of anxiety (Table 5; Additional file 1: Figure S3). Thus,
cannabis users with or without CUD have higher odds of
clinically-relevant anxiety symptoms. There was a trend
towards lack of such associations in the small subgroups
of studies without clinical diagnoses of anxiety
(Table 5; Additional file 1: Figure S3). Furthermore,
according to the meta-regression, the weighted ORswere not univariately associated with the year of publi-
cation in studies included in the current analysis
(Table 5).
Finally, even though a positive association does not pro-
vide evidence for causation, it was possible to investigate
the temporal relationship between anxiety and cannabis use
in a small subset of N = 5 studies that reported ORs for can-
nabis use at baseline and anxiety at follow-up. This analysis
showed that a cohort of those using cannabis at baseline
was significantly more likely to have symptoms of anxiety
at follow-up in studies adjusted for confounders (OR = 1.28,
95% CI: 1.06-1.54, p = .01; N = 5 studies; Figure 5A). The
opposite relationship was investigated in only one study
[29]. The results showed that there was no association
between anxiety at baseline and a regular cannabis use at
follow-up (OR = .94, 95% CI: .86-1.03; Table 3). Interest-
ingly, the one-study removed analysis (Figure 5B) showed
that the positive association between cannabis use at base-
line and anxiety at follow-up was not entirely due to the
study by Degenhardt and colleagues [41] with the largest
Table 5 Results of the moderator analyses (subgroup-analyses and univariate meta-regression)
Subgroup
of studies
Anxiety vs. cannabis use/no use Anxiety vs. CUD/no CUD (or no use)
N studies OR (95% CI) ptwo-tailed N studies OR (95% CI) ptwo-tailed
Overall mean weighted OR 15 1.24 (1.06-1.45) .006* 13 1.68 (1.23-2.31) .001*
Subgroup analyses (Figure S3)
ORs adjusted for confounders Yes 12 1.24 (1.04-1.47) .014* 10 1.66 (1.17-2.37) .005*
No 3 1.28 (.78-2.08) .326 3 1.86 (1.10-3.15) .021*
Yes vs. No Q(1) = .04; p = .848 Q(1) = 8.96; p = .003*
Clinical diagnosis of anxiety
(based on DSM/ICD)
Yes 9 1.29 (1.04-1.61) .021* 11 1.87 (1.43-2.44) <.001*
No 6 1.17 (.93-1.48) .186 2 1.14 (.78-1.66) .509
Yes vs. No Q(1) = .30; p = .586 Q(1) = 36.91; p < .001*
Meta-regression N studies slope slope ptwo-tailed N studies slope slope ptwo-tailed
Predictor: Year of publication
Outcome: weighted OR
15 .02 .299 13 -.005 .901
Note: Confounders were: other substance use and/or other substance use disorders and/or past AD and/or other psychiatric illnesses and/or demographics. The
subgroup analyses were conducted using the so-called mixed-effects model of meta-analysis [57]. According to this model the studies within each subgroup were
combined using the random-effects model. However, since the number of subgroups was fixed (rather than randomly selected out of many subgroups), the
overall mean weighted ORs in both groups were compared statistically using the between-groups Q-statistic based on the fixed-effect model of meta-analysis
with df = 1 (number of subgroups-1). This approach to comparing ORs in independent subgroups of studies is equivalent to the independent samples t-test.
Figure S3 is located in the Additional file 1.
Abbreviations: AD anxiety disorder, CUD cannabis use disorder (cannabis dependence and/or abuse/harmful use), df degrees of freedom, OR odds ratio.
*p < .05.
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http://www.biomedcentral.com/1471-244X/14/136effect size (OR = 3.20) in the analysis of N = 5 studies. How-
ever, the exclusion of the study by Brook and colleagues
[29] removed the traditional level of statistical significance
from the association, most likely due the low statistical
power of the analysis of N = 4 studies only. The inspection
of the effect sizes alone suggests that there was a trend to-
wards a consistently small and positive relationship be-
tween cannabis use at baseline and anxiety at follow-up
(OR range: 1.21-1.44) after the removal of each of the five
studies, one at a time (Figure 5B).
Discussion
The current study is the first meta-analysis to quanti-
tatively describe the relationship between anxiety and
cannabis use using data from N = 31 studies on samples
drawn from approximately 112,000 cases from the general
population of 10 countries (Australia, Canada, Columbia,
France, Germany, Netherlands, New Zealand, Switzerland,
UK, USA). The main finding of the current meta-analysis
is that cohorts with anxiety are more likely to use cannabis
(odds of 1.24) or have a cannabis use disorder (odds of
1.68; Table 4). Similarly, cohorts with concurrent anxiety
and depression are also more likely to use cannabis (odds
of 1.68; Table 4). These findings are based on samples
from the general population neither in treatment for anx-
iety nor cannabis use disorders. The current study quanti-
tatively supplements the findings of one other systematic
review on the relationship between anxiety and cannabis
use in N = 7 studies [10].
It can only be speculated that the associations above
would be higher in samples perceiving their anxiety and/or cannabis use as problematic and thus seeking profes-
sional treatment for either one or both of these condi-
tions. In support of this statement, our results show a
trend towards a higher and more stable relationship be-
tween anxiety and cannabis use disorders that might
eventually require treatment (OR = 1.68, 95% CI: 1.23-
2.31), than cannabis use alone (OR = 1.24, 95% CI: 1.06-
1.45; Table 4). Similarly, higher rates of comorbidity
would be expected in vulnerable populations often not
included in the population-based surveys due to being
homeless, imprisoned, or inpatient in psychiatric or re-
habilitation institutions [66].
All three overall effect sizes were only small and their
95% CI were close to the line of no effect (OR = 1) in the
current study (Table 4). Such small ORs were probably
due to the heterogeneous duration and definition of
‘anxiety disorders’ and ‘cannabis use/CUD’ used in the
current analysis. In general, the duration of diagnoses
and/or cannabis use/CUD ranged from within past 12
months to lifetime (Table 2). Furthermore, some studies
investigated a wide range of anxiety diagnoses according
to DSM/ICD criteria, while others focused on ‘narrow’
diagnoses, such as PTSD or OCD, only. Similarly, the
definition of ‘cannabis use’ ranged between ‘use >1×
(lifetime)’ to ‘use > daily (last 6 months)’ and the preva-
lence of particularly heavy cannabis use (>daily) was low
(Table 2). Since the total lifetime duration of cannabis
use was often not reported in studies, it was not possible
to further investigate the differences in results among
subgroups of studies with more homogenous definition,
frequency, and/or duration of cannabis use.
Study name Statistics for each study Odds ratio and 95% CI
Odds Lower Upper 
ratio limit limit p-Value
Fergusson et al. 1996 [42] 1.20 0.51 2.84 0.678
Brook et al. 1998 [28] 1.16 1.00 1.35 0.053
Brook et al. 2001 [29] 1.48 1.09 2.01 0.012
van Laar et al. 2007 [52] 1.18 0.71 1.97 0.525
Degenhardt et al. 2013 [41] 3.20 1.11 9.25 0.032
1.28 1.06 1.54 0.010
0.1 0.2 0.5 1 2 5 10
- association + association
Study name Statistics with study removed Odds ratio (95% CI) 
with study removedLower Upper 
Point limit limit p-Value
Fergusson et al. 1996 [42] 1.31 1.04 1.65 0.023
Brook et al. 1998 [28] 1.44 1.13 1.84 0.003
Brook et al. 2001 [29] 1.21 0.98 1.51 0.079
van Laar et al. 2007 [52] 1.33 1.03 1.72 0.028
Degenhardt et al. 2013 [41] 1.21 1.07 1.38 0.003
1.28 1.06 1.54 0.010
0.5 1 2
- association + association
A
B
Figure 5 Random-effects meta-analysis (A) and one-study removed analysis (B) of N = 5 studies on cannabis use at baseline and
anxiety at follow-up (all ORs adjusted for potential confounders). Notes: The top forest plot (A) shows that there was an overall positive
association between cannabis use at baseline and anxiety at follow-up in N=5 studies according to the random-effects meta-analysis (overall
mean weighted OR=1.28, 95% CI: 1.06-1.54). The bottom forest plot (B) shows the outcome of the one-study removed sensitivity analysis. ‘Point’
on plot B refers to the overall mean weighted OR of all studies without the study in each row. This analysis revealed that the positive association
between cannabis use at baseline and anxiety at follow-up was still present when the study with the largest OR in plot A (OR=3.20) was removed
from the analysis.
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http://www.biomedcentral.com/1471-244X/14/136It is interesting that the relationship between anxiety and
cannabis use was still present and positive even after con-
trolling for confounders (other substance use/psychiatric
comorbidity/demographics) in studies with mostly non-
frequent users without cannabis use disorders in the general
population (Table 5). Furthermore, such positive associ-
ation was found only in studies using cases with clinical
symptoms of anxiety disorders (according to DSM/ICD cri-
teria), but not in studies that measured severity of anxiety
using standardised scales or symptom checklists (Table 5).
It has been suggested that particularly a high-dose cannabis
use in drug-naïve users could either induce some acute
symptoms of anxiety (intense fear, panic attacks) without
necessarily causing anxiety disorders or result from with-
drawal in those with cannabis dependence [16]. Although
we have not controlled for the acute cannabis use (dose,
concentration of cannabinoids in urine, withdrawal symp-
toms), our results show that any level of cannabis use
is positively related only to clinically relevant symptoms of
anxiety. Thus, it is unlikely that the positive association be-
tween anxiety and cannabis use in the current study was
due to exclusively acute (non-clinical) symptoms of anxiety
induced by a heavy (acute) cannabis use.In terms of direction, cannabis use could further exacer-
bate existing symptoms of anxiety depending on the gen-
etic vulnerability, severity of anxiety symptoms, gender,
and age, among other factors [16]. In fact, we have found
that baseline cannabis use was indeed positively associated
with anxiety at follow-up in N = 5 studies that reported
ORs controlled for potential confounders and four of
which used the clinical diagnoses of anxiety (Figure 5). Al-
though it is tempting to state that cannabis use at baseline
caused anxiety at follow-up (Figure 5), there is little direct
evidence to support such a conclusion in the current
study. The effect size of this relationship had little statis-
tical stability in terms of only a small positive value (OR=
1.28) and the 95% confidence interval located close to
the line of no effect (OR = 1). Furthermore, other relevant
factors necessary to establish causality in epidemiological
research, such as the time order, misclassification, and
residual confounding [67,68], were not assessed in the
current analysis. Specifically, our results are based on co-
horts of cases with generally low proportions of (mostly
low-level) cannabis users who could have changed their
group membership over time due to other factors than
cannabis use alone. For example, a non-user with no
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one-off use) with a diagnosis of anxiety related to a specific
event (such as PTSD resulting from a traffic accident) at
follow-up. Another plausible alternative would be that
some cases were misclassified because of the slow onset of
some anxiety disorders or low severity of anxiety symp-
toms already present at baseline but insufficient for a
formal clinical diagnosis until a later point in time (at
follow-up). In general, a lack of longitudinal follow-up of
the same cases makes it difficult to validly and reliably
study the causation in the association between any mental
illness and cannabis use. Furthermore, the individual ORs
were adjusted for different potential confounders in the
N = 5 primary studies (Table 3). This is of importance
because our observed positive association might have re-
sulted from (a) residual confounding due to inadequate
controlling for potential confounders in primary studies as
well as our analysis and/or from (b) multiple, unmeasured
factors causally related to each other, that were not taken
into account in both the primary studies and our analysis
[67]. For example, we have used an unspecific and broad
binary criterion to classify studies based on presence/
absence of statistical adjustment of OR for any relevant
confounders in our analysis (Table 5). However, it is likely
that including specific confounders measured as scale vari-
ables would have been a more effective strategy to reduce
their direct or indirect effect on our association. One ob-
vious candidate for such a scale confounder could be
the heaviness of cannabis use measured as frequency/day,
total length of use (in years), and/or dose of cannabis/day.
Other important confounders, possibly causally related to
heaviness of cannabis use, could include age, severity of
comorbid psychiatric diagnoses, and use of other sub-
stances. However, it must be stressed that meta-analysis
utilises effect sizes based on group data from primary stud-
ies. Thus adjustments for the same (multiple) potential
confounders would need to be applied in all primary stud-
ies using individual case data to be systematically carried
over to a meta-analysis. The only sensitivity analysis that
we were able to conduct on such a small number of stud-
ies included in our analysis (N = 5) was the one-study re-
moved analysis (Figure 5B). This analysis showed that
there was a trend towards a positive (but small) association
between cannabis use at baseline and anxiety at follow-up
even after the removal of the study with the largest effect
size of OR = 3.20 [41] from this analysis. Therefore, regard-
less of causation, it appears that the relationship between
cannabis use at baseline and anxiety at follow-up is (at
most) only small.
Due to lack of data we were unable to investigate the re-
lationship between anxiety at baseline and cannabis use at
follow-up. Presence of such a (positive) relationship could
be used to support the self-medication hypothesis suggest-
ing that those with anxiety disorders could use cannabisto relax and better cope with stress [16]. The self-
medication hypothesis would also need to be investigated
taking into account the difference between the acute and
long-term effects of cannabis use and the frequency/dose/
total duration of cannabis use. In general, it appears that
cannabis has biphasic or bidirectional effect on anxiety
[18]. Thus, those with anxiety could experience some acute
relief from their symptoms after low-frequency and low-
dose cannabis use. However, a regular and heavier use
could lead to development of cannabis use disorders and,
in turn, be associated with worsening of anxiety symptoms.
These biphasic relationships could result from a dose-
dependent interaction between the active ingredient of
cannabis (delta-9-tetrahydrocannabinol) and (dysregulation
of) endocannabinoid and neurotransmitter systems, in-
cluding dopamine, GABA, glutamate, serotonin, and nor-
adrenaline [16,18]. Current results suggest that particularly
cannabis use disorders (likely resulting from heavy use) are
related to anxiety (Table 4). Similarly, dependent frequent
cannabis users, but not the frequent users without depend-
ence, had more anxiety disorders compared to the general
population [51]. Furthermore, the age of initial cannabis
use and/or development of cannabis use disorders and
anxiety symptoms might be a necessary factor to control
for when testing the association between anxiety and can-
nabis use. For example, early cannabis use may affect the
adolescent neuromaturation and cognitive functioning [69]
and thus predispose the users to subsequent development
of anxiety and other mental health problems [23]. How-
ever, genetic vulnerability to anxiety could also contribute
to poor early social and cognitive functioning, limited edu-
cational and employment prospects, and subsequent onset
of substance use [16].
The current results could have some implications for
policy making purposes. An association of a small magni-
tude between anxiety and cannabis use supports the argu-
ment that compared to the impact of other illicit drugs,
alcohol, or tobacco, the sole role of cannabis use in public
health could be judged as only modest [24] and cannabis
use is only a minor contributor to the overall disease bur-
den worldwide [8]. Thus, the current results do not pro-
vide a strong evidence for prohibiting cannabis. However,
because the two conditions co-exist at a rate higher than
statistical chance alone and, since cannabis use and anx-
iety disorders are common particularly among the youn-
ger generations, governments should focus on providing
affordable, easily accessible, and effective mental health
care. According to the World Mental Health (WMH) Sur-
veys, mental disorders, including anxiety and substance
abuse, are a crucial societal issue because they contribute
to a loss of ‘healthy life years’ in terms of reduced working
capacity and the required treatment [70]. Such a burden
should be particularly addressed in times of increased
daily stress and financial insecurity that are likely to
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Major financial problems were also identified as more im-
portant predictors of development of cannabis depend-
ence than other ‘stable’ vulnerability factors (such as
childhood adversity, own or family history of mental ill-
ness or problematic substance use, and personality) [71].
It is difficult to effectively treat comorbidity and to
quantify the recovery from such a comorbidity to a mean-
ingful life [66]. In general, patients with dual diagnoses
(problematic substance use and mental health comorbid-
ity) are more satisfied with integrated comorbidity treat-
ment than with standard treatment without explicit focus
on both diagnoses [72]. Detecting and addressing cannabis
use in patients presenting with anxiety disorders might
also be important because cannabinoids could theoretic-
ally interact with any pharmacological treatment for anx-
iety. However, the accuracy of self-reported cannabis use
depends on appropriate conditions of data collection, in-
cluding confidentiality and anonymity [73]. Such condi-
tions could in turn improve the accuracy of psychiatric
diagnosis, and contribute to more patients receiving treat-
ment for substance use disorders in the clinical practice
[74]. Since particularly the infrequent users rarely seek
professional help, it might be useful to include anxiety as
one risk associated with cannabis use in educational pro-
grams on the level of schools, community health centres,
and in the context of primary care settings [10,40]. Espe-
cially the motivational interviewing and motivational en-
hancement techniques might be useful for approaching
cannabis use disorders because young people often lack
the motivation to address their substance use and thus
miss early intervention strategies [33,50]. Reducing social
stigma and providing informal care could also contribute
to more problematic cannabis users (with cannabis use
disorders) subsequently seeking professional treatment
[75]. Furthermore, recovery from comorbidity might be
enhanced by using social networks and peer education
and support [66]. While people with comorbidity have less
supportive social networks than those with problematic
substance use alone, such networks could still be utilised
as important communication channels particularly in the
vulnerable populations [66].
The current study has a number of strengths. First,
the assessment of suitability of studies for the analysis,
deriving the extraction rules, and the data extraction
were done independently by two authors to reduce bias
in the data. This issue was particularly important be-
cause some studies reported multiple estimates of ORs.
Our procedure was also consistent with the data extrac-
tion from N = 7 studies done by Moore and colleagues
[10] (according to Figure six of their study) that were in-
cluded in our analysis. Second, the data in both meta-
analyses come from large-N, longitudinal surveys based
on representative samples from the general populationin 10 countries. Our study was more inclusive by also
extracting data from small-N, cross-sectional studies.
This approach improved the power of our analysis and
allowed us to perform three separate overall analyses
and subsequent subgroup analyses on more homogenous
subsets of studies in contrast to Moore et al. [10] who
were unable to meta-analyse the results of highly hetero-
geneous N = 7 studies. While small-N studies can be
considered unrepresentative and of poor quality com-
pared to large longitudinal studies, some of the former
included carefully screened participants and excluded
other substance users and those with other psychiatric
conditions. Therefore, the samples in these smaller stud-
ies were not necessarily of ‘worse quality’ than those in
large-scale surveys, where comorbidity with other sub-
stance use/psychiatric illness was often present and only
controlled for statistically rather than by excluding such
participants from further analyses. In addition, the
prevalence of cannabis use and/or anxiety was low in
the large longitudinal studies and, thus, the ORs in these
studies were also computed based on small Ns. Third,
the studies selected for the current analysis were per-
formed in a number of countries reducing the bias in
the results towards any one country and/or one research
team only. Although both authors of the current study
are multilingual, the search for studies was conducted in
English only because most of the largest studies on the
topic are conducted in the English-speaking, western
world (possibly due to high costs of longitudinal studies)
and/or are published in English. Consequently, even if
searching in other languages, finding of non-English
studies is more difficult because they are often not listed
on the largest scholarly databases. Finally, a systematic
assessment of publication bias with a number of tests
(funnel plots in Figures 2, 3, 4 and results in Table 4)
suggests that there was little evidence for such a bias in
the current analysis. Specifically, our meta-analysis in-
cluded studies with either positive, negative, or lack of
associations between anxiety and cannabis use/cannabis
use disorders rather than studies reporting only strong
and positive associations.
An important limitation of the current study is the litera-
ture search strategy. While Moore et al. [10] searched a
large number of databases, the current search was per-
formed on two databases only (Table 1). The rationale be-
hind this search strategy was that we expected to find the
most important sources on Medline and PsycInfo data-
bases. These two databases were also the most-relevant to
the topic databases available at our institution. Our search
strategy had failed to find N = 5 published studies from
Figure six in Moore et al. [10]. While this fact could be
considered as clear evidence for a publication bias (or at
least a poor search strategy), none of the N = 5 studies spe-
cifically addressed anxiety and cannabis use (a combination
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studies included substance use and anxiety, cannabis use
and mental health, or substance use and mental health.
Furthermore, both meta-analyses had failed to electronic-
ally locate a large longitudinal study from the USA [26]
even though the title contained the relevant search terms.
This study was obtained from our hand searches but was
omitted from Moore et al. [10] (even though it met the in-
clusion criteria of that study). Therefore, it is unlikely that
any meta-analysis would include a complete set of studies
on this topic (both published and unpublished) because, if
published, they might not be listed on major scholarly
databases, listed using non-specific terms only (such as
substance use and mental illness), and access to all print
material in all countries is hardly possible. One reasonable
compromise is to conclude that our results cannot be ex-
trapolated to the general population (of the whole world)
but rather apply to countries and samples used in the
current study alone. According to Table 2, if the same
studies are counted only once and the latest wave is used
as the total sample size/study, then the current results
apply to samples drawn from approximately 112,000 cases
from the general population of 10 countries.
Conclusions
The results of the current meta-analysis suggest that anx-
iety is positively related to cannabis use or cannabis use
disorders in cohorts, not in treatment for anxiety or can-
nabis use disorders, drawn from the general population of
10 countries. These associations were only small in magni-
tude, but were observed even after controlling for con-
founding factors (demographics, other substance use, and/
or other psychiatric comorbidity). The prospective analysis
revealed that cannabis use at baseline was positively asso-
ciated with anxiety at follow-up. While the causal direc-
tion of this relationship could not be established using the
available data, this result suggests that even infrequent
cannabis use is associated with clinically relevant symp-
toms of anxiety. Therefore, an appropriate assessment of
cannabis use might be necessary for an effective treatment
of anxiety disorders.
Additional file
Additional file 1: Supplementary Appendix.
Abbreviations
AD: Anxiety disorder; ADAD: Adolescent Drug Abuse Diagnosis (based on
Addiction Severity Index); AMD: Anxiety + depression; AP: Agoraphobia;
AUDADIS: Alcohol Use Disorders and Associated Disabilities Interview
Schedule; BAI: Beck Anxiety Inventory; CA: Cannabis abuse; CAMH: Centre for
Addiction and Mental Health Monitor survey, Canada; CanDep: The Dutch
Cannabis Dependence Study, Netherlands; CD: Cannabis dependence;
CHDS: Christchurch Health and Development Study, New Zealand;
CIDI: Composite International Diagnostic Interview; CIS-R: Clinical Interview
Schedule- Revised; CSHS: Colorado Social Health Survey, USA; CUD: Cannabisuse disorder (abuse/harmful use and/or dependence); D + : Frequent
cannabis users with dependence in CanDep study; DIS: Diagnostic Interview
Schedule; DISC: Diagnostic Interview Schedule for Children;
DMHDS: Dunedin Multidisciplinary Health and Development Study, Dunedin,
New Zealand; ECA: Epidemiological Catchment Area program, USA;
EDSP: Early Developmental Stages of Psychopathology study, Germany;
GAD: generalized anxiety disorder; GHQ-12: General Health Questionnaire
(12 items); HSC: Hopkins Symptom Checklist; K-SADS: Schedule for Affective
Disorders and Schizophrenia for School-Age Children; LIFE: Longitudinal
Interval Follow-up Evaluation; MUSP: Mater University Study of Pregnancy,
Brisbane, Australia; NCS: National Comorbidity Survey, USA; NCS-R: National
Comorbidity Survey- Replication, USA; NEMESIS/NEMESIS-2: Netherlands
Mental Health Survey and Incidence Study (study 1: 1996–1999 and study 2:
2007–2009); N2: NEMESIS-2 cases Netherlands; NESARC: National
Epidemiological Survey on Alcohol and Related Conditions, USA;
NoRMHS: The Northern Rivers Mental Health Study, New South Wales,
Australia; NPMS: The British National Psychiatric Morbidity Survey, UK;
NSMHWB: National Survey of Mental Health and Well-Being, all states,
Australia; OAD: Overanxious disorder; OCD: Obsessive compulsive disorder;
PA: Panic attacks; PD: Panic disorder; PRIME-MD: Primary Care Evaluation of
Mental Disorders; PTSD: Post-traumatic stress disorder; SA: Separation anxiety;
SAD: Social anxiety disorder/social phobia; SCID-I/NP: Structured Clinical
Interview for DSM-IV, non-patient version; SIAS: Social Interaction Anxiety
Scale; SP: Specific phobias; STAI: State-Trait Anxiety Inventory; STAI-Y: STAI for
Youth; STAI-Y A: STAI state anxiety subscale; STAI-Y B: STAI trait anxiety
subscale; T: Specific wave of data collection in longitudinal studies;
TH2K: Teen Health 2000 Study, Houston, USA; VAHCS: Victorian Adolescent
Health Cohort Study, Victoria, Australia; YASR: Young Adult Self-Report.
Competing interests
Both authors have no competing interests. There was no external funding
for this study.
Authors’ contributions
Both authors have equally contributed to this study: LTL conducted the
systematic search, extracted data from a pilot sample of N = 17 studies,
conducted preliminary analyses on these data; KKK extracted data from all
studies, conducted the final analysis, and wrote the paper; both authors
agreed on the data extraction procedure, double-checked the extracted data
from all N = 31 studies, and critically revised the paper. Both authors read
and approved the final manuscript.
Authors’ information
Dr. Karina Kedzior completed her PhD in the clinical neurosciences at the
University of Western Australia, Perth, Australia, in 2004. Her research so far
has focused on the relationship between cannabis use and neurophysiological
functioning (prepulse inhibition of the startle reflex) in cannabis users and
schizophrenia patients. She has also investigated the validity of self-reports of
cannabis and other substance use in cannabis users and schizophrenia patients,
the validity of cannabis dependence diagnoses on the CIDI, and the association
between cannabis use and depression. She is currently a Lecturer in Statistics
and Research Methods at Jacobs University Bremen, Germany, where she
teaches the traditional statistical methods (including logistic regression) and
meta-analysis. She is a co-author of four other meta-analyses.
Lisa Laeber completed her BA in Integrated Social and Cognitive Psychology
at Jacobs University Bremen, Germany, in June 2013. Throughout her degree
she studied all methods necessary for performing of the current analysis
(linear and logistic regressions, meta-analysis) and completed various courses
on advanced statistics in psychology (structural equation modelling, mixed
methods, and an ERASMUS intensive program on quantitative approaches to
psychological processes). Her bachelor thesis on the relationship between
anxiety and cannabis use in N = 17 studies submitted in April 2013 (under
the supervision of Dr. Kedzior) was used as a pilot study for the purpose of
this publication.
Acknowledgements
We would like to thank the authors of some primary studies included in the
current analysis for additional comments and data (see Table 3, ‘Data
location in study’ column). In addition, we thank the following colleagues at
Jacobs University Bremen: Ms. Anja Kakau (Systems Librarian) for her
assistance with the systematic literature search, Dr. Katja Hanke for her
Kedzior and Laeber BMC Psychiatry 2014, 14:136 Page 21 of 22
http://www.biomedcentral.com/1471-244X/14/136comments on the earlier version of this manuscript, and Mr. Patrick Kotzur
for assistance with translation from Portuguese. Finally, we thank the
following peer-reviewers for their comments on the original version of this
manuscript: Profs. Low and Zvolensky, and Ms. van der Pol.
Received: 19 July 2013 Accepted: 31 March 2014
Published: 10 May 2014
References
1. Grobe T: Gesundheitsreport 2012. Techniker Krankenkasse: Hamburg,
Germany; 2012.
2. Wittchen H-U, Jacobi F, Rehm J, Gustavsson A, Svensson M, Jönsson B,
Olesen J, Allgulander C, Alonso J, Faravelli C, Fratiglioni L, Jennum P, Lieb R,
Maercker A, van Os J, Preisig M, Salvador-Carulla L, Simon R, Steinhausen
H-C: The size and burden of mental disorders and other disorders of the
brain in Europe 2010. Eur Neuropsychopharmacol 2011, 21:655–679.
3. Kessler RC, Angermeyer M, Anthony JC, DEG R, Demyttenaere K, Gasquet I,
DEG G, Gluzman S, Gureje O, Haro JM, Kawakami N, Karam A, Levinson D,
Medina Mora ME, Oakley Browne MA, Posada-Villa J, Stein DJ, Adley Tsang
CH, Aguilar-Gaxiola S, Alonso J, Lee S, Heeringa S, Pennell BE, Berglund P,
Gruber MJ, Petukhova M, Chatterji S, Ustun TB: Lifetime prevalence and
age-of-onset distributions of mental disorders in the World Health
Organization's World Mental Health Survey Initiative. World Psychiatry
2007, 6:168–176.
4. Kessler RC, Avenevoli S, Costello EJ, Georgiades K, Green JG, Gruber MJ, He
JP, Koretz D, McLaughlin KA, Petukhova M, Sampson NA, Zaslavsky AM,
Merikangas KR: Prevalence, persistence, and sociodemographic correlates
of DSM-IV disorders in the National Comorbidity Survey Replication
Adolescent Supplement. Arch Gen Psychiatry 2012, 69:372–380.
5. Australian Bureau of Statistics: The National Survey of Mental Health and
Wellbeing (cat. no. 4326.0). Australia: ABS; 2007.
6. Degenhardt L, Chiu W-T, Sampson N, Kessler RC, Anthony JC, Angermeyer
M, Bruffaerts R, de Girolamo G, Gureje O, Huang Y, Karam A, Kostyuchenko
S, Lepine JP, Mora MEM, Neumark Y, Ormel JH, Pinto-Meza A, Posada-Villa J,
Stein DJ, Takeshima T, Wells JE: Toward a global view of alcohol, tobacco,
cannabis, and cocaine use: Findings from the WHO World Mental Health
Surveys. PLoS Med 2008, 5:e141.
7. Degenhardt L, Hall W: Extent of illicit drug use and dependence, and
their contribution to the global burden of disease. Lancet 2012,
379:55–70.
8. Degenhardt L, Ferrari AJ, Calabria B, Hall WD, Norman RE, McGrath J,
Flaxman AD, Engell RE, Freedman GD, Whiteford HA, Vos T: The global
epidemiology and contribution of cannabis use and dependence to the
global burden of disease: Results from the GBD 2010 Study. PLoS ONE
2013, 8:0076635.
9. Degenhardt L, Hall WD, Lynskey M, McGrath J, McLaren J, Calabria B,
Whiteford H, Vos T: Should burden of disease estimates include cannabis
use as a risk factor for psychosis? PLoS Med 2009, 6:29.
10. Moore THM, Zammit S, Lingford-Hughes A, Barnes TRE, Jones PB, Burke M,
Lewis G: Cannabis use and risk of psychotic or affective mental heath
outcomes: A systematic review. Lancet 2007, 370:319–328.
11. Semple DM, McIntosh AM, Lawrie SM: Cannabis as a risk factor for
psychosis: systematic review. J Psychopharmacol (Oxf ) 2005, 19:187–194.
12. Large M, Sharma S, Compton MT, Slade T, Nielssen O: Cannabis use and
earlier onset of psychosis: a systematic meta-analysis. Arch Gen Psychiatry
2011, 68:555–561.
13. Koskinen J, Lohonen J, Koponen H, Isohanni M, Miettunen J: Rate of
cannabis use disorders in clinical samples of patients with schizophrenia:
a meta-analysis. Schizophr Bull 2010, 36:1115–1130.
14. Degenhardt L, Hall W, Lynskey M: Exploring the association between
cannabis use and depression. Addiction 2003, 98:1493–1504.
15. Kedzior K, Martin-Iverson M: Association between severity of cannabis
dependence and depression. Psychology 2010, 1:233–237.
16. Crippa JA, Zuardi AW, Martín-Santos R, Bhattacharyya S, Atakan Z, McGuire
P, Fusar-Poli P: Cannabis and anxiety: A critical review of the evidence.
Hum Psychopharmacol 2009, 24:515–523.
17. Manrique-Garcia E, Zammit S, Dalman C, Hemmingsson T, Allebeck P:
Cannabis use and depression: a longitudinal study of a national cohort
of Swedish conscripts. BMC Psychiatry 2012, 12:12–112.
18. Leweke FM, Koethe D: Cannabis and psychiatric disorders: It is not only
addiction. Addict Biol 2008, 13:264–275.19. Peters EN, Budney AJ, Carroll KM: Clinical correlates of co-occurring cannabis
and tobacco use: a systematic review. Addiction 2012, 107:1404–1417.
20. Moylan S, Jacka FN, Pasco JA, Berk M: Cigarette smoking, nicotine
dependence and anxiety disorders: a systematic review of population-
based, epidemiological studies. BMC Med 2012, 10:123.
21. Moffitt TE, Harrington H, Caspi A, Kim-Cohen J, Goldberg D, Gregory AM,
Poulton R: Depression and generalized anxiety disorder: cumulative and
sequential comorbidity in a birth cohort followed prospectively to age
32 years. Arch Gen Psychiatry 2007, 64:651–660.
22. Smith JP, Randall CL: Anxiety and alcohol use disorders: comorbidity and
treatment considerations. Alcohol Res 2012, 34:414–431.
23. Wilson N, Cadet JL: Comorbid mood, psychosis, and marijuana abuse
disorders: A theoretical review. J Addict Dis 2009, 28:309–319.
24. Hall W, Lynskey M: The challenges in developing a rational cannabis
policy. Curr Opin Psychiatry 2009, 22:258–262.
25. Moher D, Liberati A, Tetzlaff J, Altman D: Preferred reporting items for
systematic reviews and meta-analyses: the PRISMA statement.
Br Med J 2009, 339:b2535.
26. Agosti V, Nunes E, Levin F: Rates of psychiatric comorbidity among U.S.
residents with lifetime cannabis dependence. Am J Drug Alcohol Abuse
2002, 28:643–652.
27. Beard JR, Dietrich UC, Brooks LO, Brooks RT, Heathcote K, Kelly B: Incidence
and outcomes of mental disorders in a regional population: the
Northern Rivers Mental Health Study. Aust N Z J Psychiatry 2006,
40:674–682.
28. Brook J, Cohen P, Brook D: Longitudinal study of co-occurring psychiatric
disorders and substance use. J Am Acad Child Adolesc Psychiatry 1998,
37:322–330.
29. Brook JS, Rosen Z, Brook DW: The effect of early marijuana use on later
anxiety and depressive symptoms. NYS Psychologist 2001, 13:35–40.
30. Buckner JD, Schmidt NB, Lang AR, Small JW, Schlauch RC, Lewinsohn PM:
Specificity of social anxiety disorder as a risk factor for alcohol and
cannabis dependence. J Psychiatr Res 2008, 42:230–239.
31. Buckner JD, Schmidt NB: Marijuana effect expectancies: Relations to social
anxiety and marijuana use problems. Addict Behav 2008, 33:1477–1483.
32. Buckner JD, Joiner TE Jr, Schmidt NB, Zvolensky MJ: Daily marijuana use
and suicidality: The unique impact of social anxiety. Addict Behav 2012,
37:387–392.
33. Cascone P, Zimmermann G, Auckenthaler B, Robert-Tissot C: Cannabis
dependence in Swiss adolescents: Exploration of the role of anxiety,
coping styles, and psychosocial difficulties. Swiss J Psychol 2011,
70:129–139.
34. Chabrol H, Ducongé E, Casas C, Roura C, Carey KB: Relations between
cannabis use and dependence, motives for cannabis use and anxious,
depressive and borderline symptomatology. Addict Behav 2005,
30:829–840.
35. Chabrol H, Chauchard E, Girabet J: Cannabis use and suicidal behaviours
in high-school students. Addict Behav 2008, 33:152–155.
36. Cheung JTW, Mann RE, Ialomiteanu A, Stoduto G, Chan V, Ala-Leppilampi K,
Rehm J: Anxiety and mood disorders and cannabis use. Am J Drug Alcohol
Abuse 2010, 36:118–122.
37. Cougle JR, Bonn-Miller MO, Vujanovic AA, Zvolensky MJ, Hawkins KA: Post-
traumatic stress disorder and cannabis use in a nationally representative
sample. Psychol Addict Behav 2011, 25:554–558.
38. Crum RM, Anthony JC: Cocaine use and other suspected risk factors for
obsessive-compulsive disorder: a prospective study with data from the
Epidemiologic Catchment Area surveys. Drug Alcohol Depend 1993,
31:281–295.
39. Degenhardt L, Hall W, Lynskey M: The relationship between cannabis use,
depression and anxiety among Australian adults: Findings from the
National Survey of Mental Health and Well-Being. Soc Psychiatry Psychiatr
Epidemiol 2001, 36:219–227.
40. Degenhardt L, Coffey C, Carlin JB, Swift W, Moore E, Patton GC: Outcomes
of occasional cannabis use in adolescence: 10-year follow-up study in
Victoria, Australia. Br J Psychiatry 2010, 196:290–295.
41. Degenhardt L, Coffey C, Romaniuk H, Swift W, Carlin JB, Hall WD, Patton GC:
The persistence of the association between adolescent cannabis use and
common mental disorders into young adulthood. Addiction 2013,
108:124–133.
42. Fergusson DM, Lynskey MT, Horwood LJ: The short-term consequences of
early onset cannabis use. J Abnorm Child Psychol 1996, 24:499–512.
Kedzior and Laeber BMC Psychiatry 2014, 14:136 Page 22 of 22
http://www.biomedcentral.com/1471-244X/14/13643. Hayatbakhsh MR, Najman JM, Jamrozik K, Mamun AA, Alati R, Bor W:
Cannabis and anxiety and depression in young adults: A large
prospective study. J Am Acad Child Adolesc Psychiatry 2007, 46:408–417.
44. Lamers CTJ, Bechara A, Rizzo M, Ramaekers JG: Cognitive function and
mood in MDMA/THC users, THC users and non-drug using controls.
J Psychopharmacol (Oxf ) 2006, 20:302–311.
45. Low NC, Lee SS, Johnson JG, Williams JB, Harris ES: The association
between anxiety and alcohol versus cannabis abuse disorders among
adolescents in primary care settings. Fam Pract 2008, 25:321–327.
46. Martins S, Gorelick D: Conditional substance abuse and dependence by
diagnosis of mood or anxiety disorder or schizophrenia in the U.S.
population. Drug Alcohol Depend 2011, 119:28–36.
47. McGee R, Williams S, Poulton R, Moffitt T: A longitudinal study of cannabis
use and mental health from adolescence to early adulthood. Addiction
2000, 95:491–503.
48. Patton GC, Coffey C, Carlin JB, Degenhardt L, Lynskey M, Hall W: Cannabis
use and mental health in young people: cohort study. Br Med J 2002,
325:1195–1198.
49. Roberts RE, Roberts CR, Xing Y: Comorbidity of substance use disorders
and other psychiatric disorders among adolescents: Evidence from an
epidemiologic survey. Drug Alcohol Depend 2007, 88S:S4–S13.
50. Swift W, Coffey C, Carlin JB, Degenhardt L, Patton GC: Adolescent cannabis
users at 24 years: trajectories to regular weekly use and dependence in
young adulthood. Addiction 2008, 103:1361–1370.
51. van der Pol P, Liebregts N, de Graaf R, Ten Have M, Korf D, van den Brink W,
van Laar M: Mental health differences between frequent cannabis users with
and without dependence and the general population. Addiction 2013.
doi:10.1111/add.12196.
52. van Laar M, van Dorsselaer S, Monshouwer K, de Graaf R: Does cannabis
use predict the first incidence of mood and anxiety disorders in the
adult population? Addiction 2007, 102:1251–1260.
53. Wittchen H-U, Fröhlich C, Behrendt S, Günther A, Rehm J, Zimmermann P,
Lieb R, Perkonigg A: Cannabis use and cannabis use disorders and their
relationship to mental disorders: A 10-year prospective-longitudinal
community study in adolescents. Drug Alcohol Depend 2007, 88:S60–S70.
54. Zvolensky MJ, Bernstein A, Sachs-Ericsson N, Schmidt NB, Buckner JD,
Bonn-Miller MO: Lifetime associations between cannabis, use, abuse, and
dependence and panic attacks in a representative sample. J Psychiatr Res
2006, 40:477–486.
55. Zvolensky MJ, Cougle JR, Johnson KA, Bonn-Miller MO, Bernstein A:
Marijuana use and panic psychopathology among a representative
sample of adults. Exp Clin Psychopharmacol 2010, 18:129–134.
56. Schmidt C, Kohlmann T: When to use the odds ratio or the relative risk?
Int J Public Health 2008, 53:165–167.
57. Borenstein M, Hedges L, Higgins J, Rothstein H: Introduction to
meta-analysis. John Wiley & Sons, Ltd: Great Britain; 2009.
58. DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials
1986, 7:177–188.
59. Rosenthal J: Qualitative descriptors of strength of association and effect
size. J Soc Serv Res 1996, 21:37–59.
60. Higgins J, Thompson S, Deeks J, Altman D: Measuring inconsistency in a
meta-analyses. Br Med J 2003, 327:557–560.
61. Rosenthal R: The ‘file drawer’ problem and tolerance for null results.
Psychol Bull 1979, 86:638–641.
62. Sterne J, Egger M: Funnel plots for detecting bias in meta-analysis:
guidelines on choice of axis. J Clin Epidemiol 2001, 54:1046–1055.
63. Duval S, Tweedie R: A nonparametric 'trim and fill' method of accounting
for publication bias in meta-analysis. J Am Statist Assoc 2000, 95:89–98.
64. Begg C, Mazumdar M: Operating characterstics of a rank correlation test
for publication bias. Biometrics 1994, 50:1088–1101.
65. Egger M, Davey S, Schneider M, Minder C: Bias in meta-analysis detected
by a simple graphical test. Br Med J 1997, 315:629–634.
66. Carter M, Fisher C, Isaac M: Recovery from comorbidity. SAGE Open 2013, 3:1–14.
67. McNamee R: Confounding and confounders. Occup Environ Med 2003,
60:227–234.
68. Shapiro S: Causation, bias and confounding: a hitchhiker's guide to the
epidemiological galaxy. Part 1. Principles of causality in epidemiological
research: time order, specification of the study base and specificity.
J Fam Plann Reprod Health Care 2008, 34:83–87.
69. Solowij N, Pesa N: Cognitive abnormalities and cannabis use. Rev Bras
Psiquiatr 2010, 32(Suppl 1):S31–S40.70. Wang PS, Aguilar-Gaxiola S, Alonso J, Angermeyer MC, Borges G, Bromet EJ,
Bruffaerts R, de Girolamo G, de Graaf R, Gureje O, Haro JM, Karam EG, Kessler
RC, Kovess V, Lane MC, Lee S, Levinson D, Ono Y, Petukhova M, Posada-Villa
J, Seedat S, Wells JE: Worldwide use of mental health services for anxiety,
mood, and substance disorders: Results from 17 countries in the WHO
World Mental Health (WMH) Surveys. Lancet 2007, 370:841–850.
71. van der Pol P, Liebregts N, de Graaf R, Korf DJ, van den Brink W, van Laar M:
Predicting the transition from frequent cannabis use to cannabis
dependence: a three-year prospective study. Drug Alcohol Depend 2013,
133:352–359.
72. Schulte SJ, Meier PS, Stirling J: Dual diagnosis clients' treatment
satisfaction - a systematic review. BMC Psychiatry 2011, 11:64.
73. Kedzior K, Badcock J, Martin-Iverson M: Validity and consistency of
self-reports regarding substance use in general research volunteers,
including regular cannabis users and schizophrenia patients. Subst Use
Misuse 2006, 41:743–750.
74. Large M, Smith G, Sara G, Paton M, Kedzior K, Nielssen O: Meta-analysis of
self-reported substance use compared with laboratory substance assay
in general adult mental health settings. Int J Meth Psych Res 2012,
21:134–148.
75. van der Pol P, Liebregts N, de Graaf R, Korf DJ, van den Brink W, van Laar M:
Facilitators and barriers in treatment seeking for cannabis dependence.
Drug Alcohol Depend 2013, 133:776–780.
doi:10.1186/1471-244X-14-136
Cite this article as: Kedzior and Laeber: A positive association between
anxiety disorders and cannabis use or cannabis use disorders in the
general population- a meta-analysis of 31 studies. BMC Psychiatry
2014 14:136.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
